Outcomes & Stories
September 10, 2026
Written by
I thought I was doing everything right
I have been conscious of cancer risk for nearly my entire adult life. I was diagnosed with testicular cancer as a teenager and underwent radiation treatment, so I had always been proactive about screening. I have annual PSA testing, regular prostate examinations, and colonoscopies starting in my mid-30s.
In December 2024, my PSA was slightly higher than it had been before. At the time, I was told that we should continue to monitor it, which didn’t seem unusual to me. I had been under surveillance for years, and “wait and see” felt like a reasonable part of that process.
Then I went to Biograph.
The finding that changed my care
In January 2025, I completed Biograph’s comprehensive assessment. Having been a cancer patient since age 17, I expected there to be discussions, concerns, and flags. Three days later, I received a call from my Biograph physician, Dr. Jim Lebret. It was after 8 p.m. on a Friday night, and I’ll always remember that call – it was obvious he phoned me the second he saw the results, regardless of the day or time.
The whole-body MRI had identified a lesion in my prostate that appeared highly concerning for cancer. There was also an abnormal finding in the bone marrow of my lower spine, raising the possibility that the cancer might have already spread.
Everything suddenly became urgent. Even though I had been receiving specialized care for years, nothing I had previously done had identified this problem. Biograph found something serious before my existing surveillance process had reached the point of acting on it.
From imaging to a treatment plan
The Biograph findings set a rapid series of events in motion. I saw a urologist, underwent additional imaging, and had a biopsy that confirmed what the Biograph team had seen.
My urologist asked to review the original Biograph images because they provided valuable information about the location and extent of the lesion. Those images, together with his own evaluation, helped inform the surgical approach. We ultimately decided to remove my prostate.
The spine finding also needed to be investigated. Biograph helped facilitate a PET scan and dedicated spine imaging, which showed that the spinal findings were not prostate cancer. They were attributed to age-related changes, prior wear, and the effects of radiation I had received earlier in life. That answer brought enormous relief.
The imaging did not replace the biopsy or my urologist’s assessment. It gave my care team important information and helped us move forward quickly.
Learning what this could mean for my family
Another major discovery was learning that I carry a genetic variant associated with increased susceptibility to certain cancers.
That information was relevant to me, but it also raised important questions for my children. It gave them knowledge they can discuss with their own healthcare professionals and consider as part of their future screening and prevention.
After living with cancer risk for so long, I thought I understood my medical history. Genetic testing gave me a different kind of information, one that could help my family make more informed decisions.
Supporting my body through treatment
My treatment did not end with surgery. Follow-up testing showed that microscopic cancer activity remained, so my care team recommended radiation and hormone therapy.
Biograph helped me think beyond the cancer itself and focus on what my body would need during treatment. Maintaining muscle mass became a major priority. To stay strong, I work with a trainer once a week and train on my own twice more, keeping my routine structured and consistent.
Hormone therapy can affect muscle and bone health, so my care plan includes monitoring my bone density and staying proactive about strength, mobility, and conditioning. I feel like I am doing everything I reasonably can to stay healthy while my clinical team manages the cancer.
A new standard for preventive care
Even though I had been receiving specialized care for years, nothing was being done that would find a serious problem until it became a serious problem. Biograph changed that.
They brought imaging, lab testing, genetic information, physician interpretation, nutrition, exercise, and follow-up planning together. Because of that, I was able to act quickly and understand more about my health than I had before.
I now feel like I am doing everything I can to be as healthy as possible, with a care team supporting me through the process.
What Robert’s story shows about proactive cancer screening
Robert’s experience shows the difference between routine surveillance and a comprehensive assessment designed to look across multiple systems.
He was already engaged in preventive care. His history of testicular cancer had led to decades of PSA testing, urology visits, and regular colonoscopies. Still, no single test had provided the full context that emerged from his Biograph assessment.
A slightly elevated PSA does not diagnose cancer on its own. In Robert’s case, whole-body MRI added critical context by showing a suspicious lesion that occupied a substantial portion of a small prostate. That finding led to specialist evaluation, biopsy, and a faster path to treatment.
His story shows how biomarkers, medical history, imaging, pathology, and clinical interpretation can work together to create a clearer picture.
Why clinical context matters in prostate cancer detection
Prostate cancer evaluation may include age, symptoms, family history, PSA history, changes in PSA over time, physical exam, imaging, and biopsy findings.
No single data point tells the whole story. A PSA result can be influenced by many factors, and its significance often depends on the person’s broader health history.
For Robert, imaging helped explain why further evaluation should happen quickly. The biopsy confirmed the diagnosis, but the MRI helped his physicians understand the size, location, and urgency of the finding.
Supporting muscle and bone health during treatment
Prostate cancer treatment can affect more than the cancer itself. Depending on the treatment plan, patients may experience changes in strength, body composition, energy, metabolic health, and bone density.
Because Robert’s treatment included hormone therapy, maintaining muscle and bone health became a priority. He works with a trainer three times a week, walks two to four miles a day, and is monitoring bone health with his care team.
This kind of support matters because treatment can place real demands on the body. Exercise, nutrition, body-composition monitoring, and bone-density assessment should be adapted to the individual, especially during active cancer treatment or recovery.
Why genetic findings can matter beyond one patient
Robert’s genetic testing identified an inherited variant associated with increased cancer susceptibility. That discovery had implications for his own care, but it also raised important questions for his children.
A genetic predisposition does not mean someone has cancer or will develop it. It can, however, help guide conversations about screening, prevention, and whether biological relatives may benefit from testing.
For Robert, genetic testing turned a personal health discovery into a broader family conversation about risk and prevention.
What may be included in a Biograph assessment
A Biograph assessment may include a range of evaluations based on clinical appropriateness and the member’s needs:
Advanced blood testing, including cardiometabolic markers
Cancer-risk assessment
Genetic risk information when clinically appropriate
DEXA body composition and bone health evaluation
Nutrition guidance
Exercise recommendations
Physician interpretation and follow-up planning
Referrals or specialist coordination when needed
The purpose is to bring multiple areas of health together so that findings can be interpreted in context and translated into appropriate next steps.
Commonly asked questions about proactive cancer screening
What is proactive cancer screening?
Proactive cancer screening uses clinically appropriate evaluation to look for potential signs of cancer before symptoms develop or disease becomes more advanced. The appropriate screening strategy varies according to age, sex, medical history, family history, inherited risk, and established clinical guidelines.
Can a whole-body MRI diagnose prostate cancer?
A whole-body MRI may identify a suspicious prostate finding, but imaging alone does not generally establish a definitive prostate cancer diagnosis. Further evaluation may include targeted imaging, specialist consultation, laboratory testing, and biopsy. Robert’s biopsy confirmed the finding initially identified through Biograph imaging.
What happens when an MRI identifies a possible abnormality?
A physician reviews the finding in the context of the patient’s history and determines whether additional evaluation is appropriate. Follow-up may involve more targeted imaging, laboratory testing, a specialist referral, surveillance, or biopsy. Many imaging findings are not cancer, but some require further investigation to reach a clear diagnosis.
How can prostate cancer treatment affect muscle and bone health?
Some prostate cancer treatments, particularly androgen deprivation therapy, may contribute to muscle loss, changes in body composition, and reduced bone density. Clinician-guided resistance training, weight-bearing exercise, adequate nutrition, and appropriate monitoring may help support physical health during treatment.
Can genetic testing help family members understand their cancer risk?
Sometimes. If testing identifies a clinically significant inherited cancer-risk variant, biological relatives may benefit from discussing genetic counseling or testing with a qualified professional. A genetic finding does not guarantee that cancer will develop, but it may influence screening and prevention decisions.
Why is follow-up important after cancer surgery?
Surgery may be one part of a broader treatment plan. Follow-up testing helps clinicians evaluate treatment response, monitor for signs of remaining or recurrent disease, and determine whether radiation, medication, hormone therapy, or continued surveillance may be appropriate.
After decades of specialized cancer surveillance, his Biograph assessment identified a prostate lesion that led to further evaluation and treatment. He shares how comprehensive testing, physician coordination, and personalized nutrition and exercise support helped him take a more proactive role in his health and recovery.
